Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FLT3 in human hematologic malignancies.

Hitoshi Kiyoi1, Tomoki Naoe

  • 1Department of Infectious Diseases, Nagoya University School of Medicine, Japan. kiyoi@med.nagoya-u.ac.jp

Leukemia & Lymphoma
|October 29, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

British journal of haematology·2026
Same author

Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML.

Blood advances·2026
Same author

Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

Blood advances·2026
Same author

BATF3 regulates differentiation of CD8<sup>+</sup> T lymphocytes and memory differentiation program.

Life science alliance·2026
Same author

Ponatinib inhibits LCK and PI3K signaling and promotes CD8<sup>+</sup> T stem cell memory cell development.

Nature communications·2026
Same author

CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.

Journal for immunotherapy of cancer·2026

FLT3 mutations are common in acute myeloid leukemia (AML) and linked to poor prognosis. Targeting FLT3 kinase presents a promising therapeutic strategy for leukemia treatment.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • FLT3 (FMS-like tyrosine kinase 3) is a receptor tyrosine kinase (RTK) class III.
  • FLT3 is expressed on hematopoietic stem cells and implicated in normal hematopoiesis.
  • FLT3 is also found on leukemia cells in acute myeloid leukemia (AML) and B-lineage acute lymphocytic leukemia (ALL).

Purpose of the Study:

  • To review the clinical and biological significance of FLT3 mutations in AML.
  • To explore the potential of targeting FLT3 kinase for leukemia therapy.

Main Methods:

  • Literature review of studies on FLT3 mutations in AML.
  • Analysis of clinical data associating FLT3 mutations with patient outcomes.

Main Results:

Related Experiment Videos

  • FLT3 mutations, including internal tandem duplication (ITD) and D835 missense mutations, are frequent in AML (20% and 6% respectively).
  • FLT3 ITD mutations are associated with leukocytosis and poor prognosis in AML patients.
  • FLT3 signaling is crucial for the survival and proliferation of both normal hematopoietic and leukemia cells.

Conclusions:

  • FLT3 mutations represent the most frequent genetic alterations in AML.
  • Targeting FLT3 kinase is a viable therapeutic avenue for treating AML and potentially other leukemias.